Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus to report Q3 2025 results after market close on November 4, 2025

Neutral Impact 2 of 5 earnings Written later

Supernus Pharmaceuticals announced it will report third quarter 2025 financial and business results after the market closes on Tuesday, November 4, 2025, and host a conference call and webcast that day at 4:30 p.m. ET. The announcement is a scheduling notice and contains no financial results, so it gives shareholders no new information on performance.

Key points

  • Third quarter 2025 results expected after market close on Tuesday, November 4, 2025
  • Conference call and webcast scheduled for November 4, 2025 at 4:30 p.m. ET
  • CEO Jack Khattar and CFO Tim Dec will present the results on the call

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECOct 21, 2025, 5:05 PM ET
Accession number0001356576-25-000065

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.